{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:59:56Z","timestamp":1791046796107,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.leukres.2009.08.031","type":"journal-article","created":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T11:59:46Z","timestamp":1253793586000},"page":"129-134","source":"Crossref","is-referenced-by-count":53,"title":["Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.08.031_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2009.08.031_bib2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.08.031_bib3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1 positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cncr.11520","article-title":"Chronic myelogenous leukaemia: a review and update of therapeutic strategies","volume":"98","author":"Garcia-Manero","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2009.08.031_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1081\/CNV-120018235","article-title":"STI571 as a targeted therapy for CML","volume":"21","author":"O\u2019Dwyer","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1016\/j.leukres.2009.08.031_bib7","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imagine as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib8","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.08.031_bib10","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.08.031_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/187152909787581363","article-title":"Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem","volume":"9","author":"Breccia","year":"2009","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.leukres.2009.08.031_bib13","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2009.08.031_bib14","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminhematol.2006.12.002","article-title":"Resistance to targeted therapy in chronic myelogenous leukemia","volume":"44","author":"Hochhaus","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2009.08.031_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2009.08.031_bib16","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.08.031_bib17","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","article-title":"Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases","volume":"14","author":"Manley","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.leukres.2009.08.031_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2009.08.031_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.leukres.2009.08.031_bib20","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood.V112.11.3205.3205","article-title":"Nilotinib concentration in cell lines and CML CD34+ cells is not mediated by active uptake or efflux by major drug transporters","volume":"112","author":"Mountford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2009.08.031_bib22","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.08.031_bib23","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2009.08.031_bib24","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib25","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR\u2013ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib26","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1182\/blood.V112.11.3216.3216","article-title":"Nilotinib efficacy according to baseline BCR\u2013ABL mutations in patients with imatinib-resistant chronic myeloid leukemia in chronic phase (CML\u2013CP)","volume":"112","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib27","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR\u2013ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib28","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1182\/blood-2006-11-058032","article-title":"Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs","volume":"109","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib29","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"New Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.08.031_bib30","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CML\u2013CP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study","volume":"94","author":"Kantarjian","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.08.031_bib31","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood.V112.11.3181.3181","article-title":"Lyn Kinase overexpression is one of the mechanisms of resistance to nilotinib in chronic myeloid leukemia","volume":"112","author":"Mahon","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.08.031_bib32","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study","volume":"94","author":"Hochhaus","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.08.031_bib33","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood.V112.11.3233.3233","article-title":"Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML\u2013CP) with imatinib resistance or intolerance: efficacy and safety analysis","volume":"112","author":"Lipton","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.08.031_bib34","article-title":"Final safety analysis of 1793 patients from ENACT (expanding nilotinib access in clinical trials) study in adult patients with imatinib resistant or intolerant chronic myeloid leukemia (CML)","volume":"94","author":"Nicolini","year":"2009","journal-title":"Haematologica"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.08.031_bib35","article-title":"Expanding nilotinib access in clinical trials (ENACT) study in adult patients with imatinib resistant or intolerant chronic myeloid leukemia (CML): subgroup analysis of patients who failed prior dasatinib therapy","volume":"94","author":"Nicolini","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.08.031_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-02-073528","article-title":"Nilotinib in patients with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who are resistant or intolerant to imatinib","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib37","article-title":"Nilotinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib","volume":"110","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.031_bib38","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood.V112.11.3215.3215","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-Intolerant chronic myeloid leukemia in chronic phase (CML\u2013CP) or accelerated phase (CML-AP)","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.08.031_bib39","article-title":"No inhibition of warfarin pharmacokinetics and pharmacodynamics by nilotinib in human subjects","volume":"94","author":"Yin","year":"2009","journal-title":"Haematologica"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.08.031_bib40","article-title":"Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib","volume":"94","author":"Yin","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.08.031_bib41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.V112.11.446.446","article-title":"Efficacy of Nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML\u2013CP)","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2009.08.031_bib42","article-title":"Nilotinib 800mg daily in early chronic phase myeloid leukemia: 12-months results of a phase 2 trial of the GIMEMA CML Working Party","volume":"94","author":"Rosti","year":"2009","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609004408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609004408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T12:47:55Z","timestamp":1590151675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609004408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0145212609004408"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.08.031","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}